Patent classifications
C
CHEMISTRY; METALLURGY
Load children
C07
ORGANIC CHEMISTRY
Load children
C07D
HETEROCYCLIC COMPOUNDS
Load children
241/00
Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
Load children Filter patents View analytics View as hierarchy Open in page
C07D241/02
not condensed with other rings
Load children Filter patents View analytics View as hierarchy Open in page
C07D241/10
having three double bonds between ring members or between ring members and non-ring members
Load children Filter patents View analytics View as hierarchy Open in page
C07D241/14
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Load children Filter patents View analytics View as hierarchy Open in page
C07D241/24
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Load children Filter patents View analytics View as hierarchy Open in page
C07D241/26
with nitrogen atoms directly attached to ring carbon atoms
Load children Filter patents View analytics View as hierarchy Open in page
C07D241/28
in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
Load children Filter patents View analytics View as hierarchy Open in page
C07D241/30
in which said hetero-bound carbon atoms are part of a substructure —C(=X)—X—C(=X)—X— in which X is an oxygen or sulphur atom or an imino radical, e.g. imidoylguanidines
Load children Filter patents View analytics View as hierarchy Open in page
C07D241/32
(Amino-pyrazinoyl) guanidines
Filter patents View analytics View as hierarchy Open in page

C07D241/32

3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS
20170362187 · 2017-12-21 · ·

The present invention relates compounds of the formula:

##STR00001##

or pharmaceutically acceptable salts thereof, useful as sodium channel blockers, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, acute and chronic bronchitis, emphysema, and pneumonia.

CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY
20170327472 · 2017-11-16 · ·

This invention provides compounds of the formula I:

##STR00001##

and their pharmaceutically acceptable salts, useful as sodium channel blockers, compositions containing the same, therapeutic methods and uses for the same and processes for preparing the same.

ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS
20170305868 · 2017-10-26 · ·

The present invention relates to the compound of the formula:

##STR00001##

or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.

ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS
20170305868 · 2017-10-26 · ·

The present invention relates to the compound of the formula:

##STR00001##

or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.

CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY
20170281620 · 2017-10-05 · ·

A very stable, selective and renally safe sodium channel blocker represented by the formula:

##STR00001##

The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.

CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY
20170281620 · 2017-10-05 · ·

A very stable, selective and renally safe sodium channel blocker represented by the formula:

##STR00001##

The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.

3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine-2-carboxamide compounds
09695134 · 2017-07-04 · ·

The present invention relates compounds of the formula: ##STR00001##
or pharmaceutically acceptable salts thereof, useful as sodium channel blockers, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, acute and chronic bronchitis, emphysema, and pneumonia.

Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
09655896 · 2017-05-23 · ·

A very stable, selective and renally safe sodium channel blocker represented by the formula: ##STR00001## The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.

Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
09655896 · 2017-05-23 · ·

A very stable, selective and renally safe sodium channel blocker represented by the formula: ##STR00001## The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.

Compounds for treatment of cystic fibrosis
09656972 · 2017-05-23 · ·

Described herein are compounds, compositions, and methods of their use for the treatment of cystic fibrosis.